Alexander Monto

Summary

Country: USA

Publications

  1. ncbi Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop
    Alexander Monto
    Department of Medicine, San Francisco Veterans Affairs Medical Center, San Francisco, California 94121, USA
    Am J Gastroenterol 105:989-1004; quiz 988, 1005. 2010
  2. ncbi Liver disease in injection drug users with hepatitis C, with and without HIV coinfection
    Alexander Monto
    San Francisco Veterans Affairs Medical Center, CA, USA
    J Addict Dis 27:49-59. 2008
  3. ncbi Contributions to hepatic fibrosis in HIV-HCV coinfected and HCV monoinfected patients
    Alexander Monto
    Gastroenterology Section, Veterans Affairs Medical Center, San Francisco, California 94121, USA
    Am J Gastroenterol 101:1509-15. 2006
  4. ncbi Risks of a range of alcohol intake on hepatitis C-related fibrosis
    Alexander Monto
    Department of Gastroenterology, University of California at San Francisco, 4150 Clement Street 111B, San Francisco, CA 94121, USA
    Hepatology 39:826-34. 2004
  5. ncbi Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection
    Alexander Monto
    Gastroenterology Section, Veterans Affairs Medical Center, University of California, 4150 Clement Street 111B, San Francisco, CA 94121, USA
    Hepatology 42:310-6. 2005
  6. ncbi Non-Markov multistate modeling using time-varying covariates, with application to progression of liver fibrosis due to hepatitis C following liver transplant
    Peter Bacchetti
    University of California, San Francisco, CA, USA
    Int J Biostat 6:Article 7. 2010
  7. ncbi Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study
    Helen S Yee
    Gastroenterology Section, Department of Veterans Affairs Medical Center VAMC, 4150 Clement Street 111B, San Francisco, CA 94121, USA
    Dig Dis Sci 56:2439-48. 2011
  8. ncbi Hepatocellular carcinoma after sustained virologic response in hepatitis C patients without cirrhosis on a pretreatment liver biopsy
    Justin L Sewell
    Gastroenterology Section, University of California San Francisco, San Francisco, California 94143, USA
    Eur J Gastroenterol Hepatol 21:225-9. 2009
  9. ncbi The human fetal immune response to hepatitis C virus exposure in utero
    Jennifer M Babik
    Division of Experimental Medicine, Department of Medicine, University of California, San Francisco, CA 94143 1234, USA
    J Infect Dis 203:196-206. 2011
  10. ncbi A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus
    Sue L Currie
    Department of Medicine, University of California San Francisco, San Francisco, CA 94121, USA
    Drug Alcohol Depend 93:148-54. 2008

Detail Information

Publications16

  1. ncbi Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop
    Alexander Monto
    Department of Medicine, San Francisco Veterans Affairs Medical Center, San Francisco, California 94121, USA
    Am J Gastroenterol 105:989-1004; quiz 988, 1005. 2010
    ..This article summarizes that conference...
  2. ncbi Liver disease in injection drug users with hepatitis C, with and without HIV coinfection
    Alexander Monto
    San Francisco Veterans Affairs Medical Center, CA, USA
    J Addict Dis 27:49-59. 2008
    ..Limiting liver disease progression in IDUs with hepatitis C may well be best accomplished through promoting their full utilization of health care...
  3. ncbi Contributions to hepatic fibrosis in HIV-HCV coinfected and HCV monoinfected patients
    Alexander Monto
    Gastroenterology Section, Veterans Affairs Medical Center, San Francisco, California 94121, USA
    Am J Gastroenterol 101:1509-15. 2006
    ..Immune compromise plays an important role in liver disease in coinfected patients, and the role of other clinical factors in liver disease may differ between these two groups, as well...
  4. ncbi Risks of a range of alcohol intake on hepatitis C-related fibrosis
    Alexander Monto
    Department of Gastroenterology, University of California at San Francisco, 4150 Clement Street 111B, San Francisco, CA 94121, USA
    Hepatology 39:826-34. 2004
    ..Age, serum ALT, and inflammation are independently associated with fibrosis in multivariate analysis, highlighting the fact that variables other than alcohol intake predominate in the production of hepatic fibrosis...
  5. ncbi Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection
    Alexander Monto
    Gastroenterology Section, Veterans Affairs Medical Center, University of California, 4150 Clement Street 111B, San Francisco, CA 94121, USA
    Hepatology 42:310-6. 2005
    ..In conclusion, steatosis is less common in HIV/HCV coinfected patients than similar HCV monoinfected patients, and predictors of steatosis differ between the two groups...
  6. ncbi Non-Markov multistate modeling using time-varying covariates, with application to progression of liver fibrosis due to hepatitis C following liver transplant
    Peter Bacchetti
    University of California, San Francisco, CA, USA
    Int J Biostat 6:Article 7. 2010
    ....
  7. ncbi Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study
    Helen S Yee
    Gastroenterology Section, Department of Veterans Affairs Medical Center VAMC, 4150 Clement Street 111B, San Francisco, CA 94121, USA
    Dig Dis Sci 56:2439-48. 2011
    ..As such, CIFN/RBV use and efficacy in clinical practice were evaluated within the Department of Veterans Affairs (VA), the largest national, integrated system for HCV care...
  8. ncbi Hepatocellular carcinoma after sustained virologic response in hepatitis C patients without cirrhosis on a pretreatment liver biopsy
    Justin L Sewell
    Gastroenterology Section, University of California San Francisco, San Francisco, California 94143, USA
    Eur J Gastroenterol Hepatol 21:225-9. 2009
    ..As fibrosis may advance, and because SVR and lack of cirrhosis do not fully protect against HCC, future study should further evaluate the risk of HCC among hepatitis C patients after sustained virologic response...
  9. ncbi The human fetal immune response to hepatitis C virus exposure in utero
    Jennifer M Babik
    Division of Experimental Medicine, Department of Medicine, University of California, San Francisco, CA 94143 1234, USA
    J Infect Dis 203:196-206. 2011
    ..Although the rate of mother-to-child transmission of hepatitis C virus (HCV) is low, the effect of HCV exposure in utero on the fetal immune system is unknown...
  10. ncbi A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus
    Sue L Currie
    Department of Medicine, University of California San Francisco, San Francisco, CA 94121, USA
    Drug Alcohol Depend 93:148-54. 2008
    ..Many HCV-infected persons with recent or ongoing injection drug use (IDU) do not receive HCV treatment due to the perceived risk of HCV reinfection. There are few prospective studies investigating HCV reinfection among IDUs...
  11. ncbi Periprocedural complications by Child-Pugh class in patients undergoing transcatheter arterial embolization or chemoembolization to treat unresectable hepatocellular carcinoma at a VA medical center
    Jeffery S Russell
    Department of Medicine, University of California, San Francisco, Medical Center, USA
    Am J Surg 200:659-64. 2010
    ..The aim of this study was to compare periprocedural complications in a population with hepatitis C virus-related hepatocellular carcinoma to evaluate for differences in complications by severity of liver disease...
  12. ncbi Association of hepatitis C virus seropositivity with inflammatory markers and heart failure in persons with coronary heart disease: data from the Heart and Soul study
    Judith I Tsui
    Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine Boston Medical Center, Boston, MA 02118, USA
    J Card Fail 15:451-6. 2009
    ..How hepatitis C virus (HCV) affects coronary heart disease (CHD) risk factors and outcomes is largely unknown...
  13. ncbi Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol
    Alexander Monto
    Department of Veterans Affairs Medical Center, University of California, San Francisco, San Francisco, CA 94121, USA
    Hepatology 36:729-36. 2002
    ..Significant alcohol or NASH injury was found in only 6% of biopsy specimens. In conclusion, steatosis in HCV infection is associated with risk factors for NASH, particularly obesity, rather than alcohol consumption...
  14. ncbi Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo
    Satish K Pillai
    Department of Medicine, University of California, San Francisco, CA 94143, USA
    Proc Natl Acad Sci U S A 109:3035-40. 2012
    ....
  15. ncbi Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C
    Hongjin Huang
    Celera Diagnostics, Alameda, California, USA
    Gastroenterology 130:1679-87. 2006
    ..The aim of this study was to identify genetic polymorphisms that can predict the risk of advanced fibrosis in patients with CHC...
  16. ncbi Fibrosis progression in chronic hepatitis C patients with occult hepatitis B co-infection
    Chee Kin Hui
    Department of Medicine, The University of Hong Kong, Hong Kong SAR, China
    J Clin Virol 35:185-92. 2006
    ..946). In conclusion, chronic HCV patients with occult HBV co-infection does not seem to progress more than patients without occult HBV infection. However, more large-scale studies are needed before a definite conclusion can be obtained...